|
|||||
![]() |
|
Financial services provider CBIZ (NYSE:CBZ) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 62.7% year on year to $683.5 million. On the other hand, the company’s full-year revenue guidance of $2.88 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $0.95 per share was 12.6% above analysts’ consensus estimates.
Is now the time to buy CBZ? Find out in our full research report (it’s free).
CBIZ’s second quarter results were met with a significant negative market reaction, as revenue growth lagged Wall Street’s expectations despite a substantial year-on-year increase. Management highlighted persistent headwinds in discretionary, project-based services, which clients are delaying amid economic uncertainty. CEO Jerry Grisko described the quarter’s environment as “anything but stable and certain,” attributing the softness to client caution on nonessential spending and increased pushback on pricing, particularly in areas most sensitive to macroeconomic conditions.
Looking ahead, management’s guidance reflects a cautious outlook for the remainder of the year, with expectations that current market conditions will persist. Grisko emphasized, “We expect continued steady demand for our core recurring essential businesses to provide line of sight to the lower end of our revenue guidance, even as nonrecurring services face ongoing headwinds.” The integration of Marcum is expected to drive incremental margin improvements and expand the company’s service capabilities, while ongoing cost controls and targeted revenue initiatives are intended to partially offset pressures in more volatile business lines.
Management pointed to the Marcum acquisition and disciplined cost actions as key drivers of margin expansion, while acknowledging that weaker discretionary demand and inflationary pressures are weighing on growth in certain segments.
CBIZ’s forward outlook is anchored by steady demand for core services, ongoing cost discipline, and the anticipated benefits of the Marcum integration, though persistent uncertainty in discretionary service demand and pricing will weigh on growth.
In the coming quarters, our analysts will be closely watching (1) the pace and effectiveness of Marcum integration and realization of targeted cost synergies, (2) whether pricing discipline can improve in an environment of client cost sensitivity, and (3) any signs of recovery in project-based and SEC-related revenue streams. Execution on cross-selling initiatives and progress on deleveraging will also be important to monitor.
CBIZ currently trades at $62.91, down from $76.22 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
1 hour | |
Aug-19 | |
Aug-13 | |
Aug-12 | |
Aug-07 | |
Aug-05 | |
Jul-31 | |
Jul-31 | |
Jul-30 | |
Jul-30 | |
Jul-30 | |
Jul-30 | |
Jul-28 | |
Jul-22 | |
Jul-16 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite